Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
Some research suggests that whole-plant cannabis compounds (like THC, CBD, other cannabinoids, terpenes, and flavonoids) can interact so the plant’s effects differ from CBD alone. Healthline explains three CBD types — full-spectrum, broad-spectrum, and isolate — and notes legal, safety, and labeling limits. The article says there is evidence for…
In rats and mice that had brain lesions used to model Parkinson's disease, the plant compound Δ9-THCV reduced movement problems after a single dose and, with repeated dosing, reduced loss of dopamine-producing neurons in the brain region called the substantia nigra. Some effects seem linked to antioxidant actions and, in…
This study tested Δ9‑tetrahydrocannabinolic acid (Δ9‑THCA), the acidic form of THC, in lab cells and in mice. The researchers found that Δ9‑THCA activates the nuclear receptor PPARγ more strongly than neutral cannabinoids, increased mitochondrial mass in neuroblastoma cells, reduced cell damage caused by mutant huntingtin in cell models, and improved…
This study tested the cannabis-related compound THCV in lab and rat experiments. In lab tests on rat brain membranes and human cells, 100 nM THCV increased activation of the serotonin 5-HT1A receptor and changed how a 5-HT1A probe bound to the receptor. In rats treated with phencyclidine (a model for…
This study tested tetrahydrocannabinolic acid (THCA) in animal models of nausea and vomiting. In rats, THCA at 0.05 and 0.5 mg·kg−1 reduced LiCl-induced conditioned gaping, a behavior linked to nausea. In the house musk shrew (Suncus murinus), the same THCA doses reduced LiCl-induced vomiting. These effects were reversed by the…
This study tested Δ9‑tetrahydrocannabinolic acid A (Δ9‑THCA‑A), a non‑psychotropic cannabis compound, in lab cells and in a mouse model of rheumatoid‑type arthritis. The compound acted at cannabinoid CB1 receptors in two ways (as an orthosteric agonist and as a positive allosteric modulator), appeared to act oppositely at CB2 receptors, activated…
